Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxxon Therapeutics Ltd.

Division of Oxford BioMedica PLC
www.oxti.com

Latest From Oxxon Therapeutics Ltd.

European Biotech Is Specialty Pharma

Europe's investment environment has forced much of the biotech sector to morph into specialty pharma. The situation isn't likely to change fast. Executives had best adapt, rather than complain.
BioPharmaceutical Europe

The US: To Go, or Not to Go?

Whether or not European biotechs should establish operations in the US may seem like a no brainer: it's the biggest drugs market, with more potential partners, better funding, more promising exits for investors and a more experienced management pool than Europe. But getting there-and getting noticed-isn't easy. And since most executives agree that going to the US half-heartedly isn't worthwhile, Europe's biotechs need to think hard about when and whether they're ready to go. For a minority, setting up in the US may not be the right solution-for now.
Europe United States

immatics biotechnologies GMBH

immatics biotechnologies GMBH aims to identify tumor-associated peptides by directly measuring their presence in cancer tissue and then creating cancer vaccines from combinations of the most prevalent peptides associated with a particular tumor. The Tuebingen-based firm's proprietary platform combines genomics, mass spectrometry and cell-based assay systems to offer better speed and precision than existing technologies.
BioPharmaceutical Europe

Clinical Trials Directive: Another Factor Against Europe?

The EU Clinical Trials Directive aims to encourage harmonization of clinical trial procedures throughout the Union, but in fact will impose additional cost and administrative burdens likely to drive biotech firms away from Europe. More frustratingly still, the directive still doesn't allow companies to conduct trials anywhere across the continent.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Oxxon Pharmaccines Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Oxford BioMedica PLC
  • Senior Management
  • Atusha Patel, PhD, Dir., Bus. Dev.
    Emma Johnson, Head, Finance
    Joerg Schneider, PhD, VP, Research
  • Contact Info
  • Oxxon Therapeutics Ltd.
    Phone: (44) 1865 398 100
    Florey House, 3 Robert Robinson Ave.
    2nd Fl.
    Oxford, OX4 4GP
    UK
UsernamePublicRestriction

Register